Liquidity As at March 31, 2022, we had $0.5 million of cash. We need to raise additional capital to fund research, development and corporate activities over the next year which include continued clinical development or we may be forced to cease operations. As at March 31, 2022, we were committed to pay $11.6 million of current trade and other payables, $1.4 million for research and development commitments, and $0.6 million of lease liabilities over the next twelve months. Furthermore, our $6.0 million debenture with Hepalink is due on May 13, 2023

As at March 31, 2023, we had $3 thousand of cash. We need to raise additional capital to fund research, development and corporate activities over the next year which include continued clinical development, or we may be forced to cease operations. As at March 31, 2023, we were committed to pay $14.6 million of current trade and other payables, $1.4 million for research and development commitments, and $0.3 million of lease liabilities over the next twelve months. Furthermore, our $6.0 million debenture with Hepalink is due on May 13, 2024